Molecular Analysis of Thrombocytopenia and Cancer (MATAC): Investigating Antigenic Mimicry Between Platelets and Tumor Cells in Patients With Immune Thrombocytopenia (ITP) Associated With Cancer

Cancer Clinical Trial

— MATAC  

Official title:

Molecular Analysis of Thrombocytopenia and Cancer (MATAC): Investigating Antigenic Mimicry Between Platelets and Tumor Cells in Patients With Immune Thrombocytopenia (ITP) Associated With Cancer

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06444477
• Other study ID #: CHUBX 2024/16
• Status: Not yet recruiting
• Start date: June 2024
• Est. completion date: December 2024

Study information

• Verified date: May 2024
• Source: University Hospital, Bordeaux
• Contact: Etienne RIVIERE, MD
• Phone: (0)557656483
• Email: etienne.riviere[@]chu-bordeaux.fr
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The association between hematologic malignancies and ITP is well described, but this link is much less clear with solid cancers. In cases of ITP associated with cancers, specific cancer treatment can lead to remission or even cure of ITP. Thus, our hypothesis was that chronic expression of GPIIB by tumor cells could have initiated an autoimmune loop against GPIIB, leading to the onset and perpetuation of ITP.

Description:

Autoimmune thrombocytopenia, also known as immune thrombocytopenic purpura (ITP), is a rare autoimmune disease characterized by platelet destruction and impaired production, posing a life-threatening risk due to bleeding complications. The pathophysiology of ITP involves complex mechanisms, including both defective platelet production and auto-reactivity of B and T lymphocytes leading to the production of autoantibodies against platelets, found in 35 to 55% of cases. Additionally, in the context of neoplasia, some patients may develop varying degrees of thrombocytopenia, exacerbating morbidity and mortality. A multicenter, retrospective study will collect data from routine care, including birth date, gender, biological parameters related to ITP, dates of treatment initiation and diagnosis of ITP and cancer, types of treatments, and outcomes such as survival or death, without additional medical interventions or appointments.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 70
• Est. completion date: December 2024
• Est. primary completion date: December 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Adult patients with a definite diagnosis of both ITP and cancer;
• Synchronous diagnosis of ITP and cancer;
• Onset of ITP occurring 6 months before or after the diagnosis of cancer.

Exclusion Criteria:

• None

Related Conditions & MeSH terms

• Cancer
• Immune Thrombocytopenia
• Immune Thrombocytopenic Purpura
• Neoplasms
• Purpura
• Purpura, Thrombocytopenic
• Purpura, Thrombocytopenic, Idiopathic
• Thrombocytopenia

Intervention

Other:
• ITP and cancer
ITP and cancer

Locations

Country	Name	City	State
France	AP-HP Hôpital Jean Verdier service de médecine interne	Bondy
France	CHU de Clermont-Ferrand - service de médecine interne	Clermont-Ferrand
France	AP-HP Hôpital Mondor service de médecine interne	Créteil
France	AP-HP Hôpital Bicêtre service de médecine interne	Le Kremlin-Bicêtre
France	CHU de Lille - service d'Hématologie	Lille
France	HCL - service d'Hématologie	Lyon
France	AP-HM Hôpital la Timone - service de médecine interne	Marseille
France	CHU de Montpellier - service d'Hématologie	Montpellier
France	CHRU de Nancy - service de Médecine Interne et Immunologie Clinique	Nancy
France	CHU de Nantes - service de médecine interne	Nantes
France	CHRU d'Orléans - service de Médecine interne	Orléans
France	CHRU d'Orléans - service de réanimation	Orléans
France	AP-HP Hôpital Bichat service de médecine interne	Paris
France	AP-HP Hôpital Saint-Antoine service de médecine interne	Paris
France	AP-HP Hôpital Saint-Louis service immuno-hématologie	Paris
France	CHU de Bordeaux Service de Médecine Interne et Maladies Infectieuses	Pessac
France	CHU de Poitiers - service de médecine interne	Poitiers
France	CHRU de Strasbourg - service de médecine interne	Strasbourg
France	CHU de Toulouse - service de médecine interne	Toulouse
France	CHU de Tours - service de médecine interne	Tours

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital, Bordeaux

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Remission rate of ITP at 6 months after specific cancer treatment		At baseline (Day 0)
Secondary	All-cause mortality		At baseline (Day 0)
Secondary	Side effects related to ITP and its treatment		At baseline (Day 0)
Secondary	Side effects related to its treatment		At baseline (Day 0)
Secondary	Clinical description of the characteristics of ITP associated with a diagnosis of solid cancer		At baseline (Day 0)
Secondary	Biological description of the characteristics of ITP associated with a diagnosis of solid cancer		At baseline (Day 0)
Secondary	Demographic description of the characteristics of ITP associated with a diagnosis of solid cance		At baseline (Day 0)
Secondary	Therapeutic description of the characteristics of ITP associated with a diagnosis of solid cance		At baseline (Day 0)